Decision details

Discretionary Rates Relief for Labcorp Drug Development (formerly known as Covance by Labcorp)

Reference: D54528

Decision Maker: Director of Resources

Decision status: Recommendations Approved

Is Key decision?: No

Is subject to call in?: No


The Chief Officer Financial Services has approved the request from Labcorp Drug Development for business rates relief at £335,000 over a three year period from FY21/22 and the rates relief be released incrementally over 3 years as follows: 40% in FY 2021/22 (£134,000), 40% in 2022/23 (£134,000) and 20% in 2023/24 (£67,000).

Wards Affected: Beeston and Holbeck;

Contact: Tariq Sadiq, Inward Investment Manager 0113 378 6971 Email:

Publication date: 01/10/2021

Accompanying Documents: